David Beck
Medical · Glendale, AZNPI 1679646350
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.4% of the total across 331 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,387 and has fallen 78.2% since, to $738 in 2025. Among medical clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 331 payments — averaging $25.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$1K
- Biohaven Pharmaceuticals, Inc.$981
- AbbVie$854
- Boehringer Ingelheim$712
- Amgen$668
- plus $3K from 24 others
What the payments were for
- Consulting fees$80010%
- Food & beverage$7,52190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $1,182 |
| Novo Nordisk | 43 | $1,060 |
| Biohaven Pharmaceuticals, Inc. | 5 | $981 |
| AbbVie | 45 | $854 |
| Boehringer Ingelheim | 32 | $712 |
| Amgen | 24 | $668 |
| Lilly USA, LLC | 34 | $531 |
| Abbott | 16 | $389 |
| GSK | 23 | $299 |
| Pfizer | 16 | $293 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $195 |
| Boston Scientific | 4 | $187 |
| Sanofi-aventis U.S. LLC | 4 | $154 |
| Sanofi | 1 | $122 |
| Johnson & Johnson | 4 | $81 |
| Novartis | 4 | $75 |
| Exact Sciences | 4 | $72 |
| Kowa Pharmaceuticals America, Inc. | 5 | $71 |
| Vanda Pharmaceuticals Inc. | 4 | $67 |
| Merck | 4 | $59 |
| Inspire Medical Systems, Inc. | 2 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $47 |
| Eisai Inc. | 2 | $37 |
| Nevro Corp. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| Bayer | 1 | $19 |
| Celltrion USA Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $15 |
| Vistapharm, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$925
- Repatha$361
- BREZTRI$240
- Ozempic$228
- RYBELSUS$125
- Watchman$125
- DUPIXENT$122
- QULIPTA$117
- UBRELVY$117
- TRELEGY ELLIPTA$113
- FARXIGA$109
- SOLIQUA 100/33$102
How this compares
$8,321 in reported general payments places this provider in the 90th percentile of 748 medical providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 91 | $88,162 |
| FarxigaDapagliflozin Propanediol | 78 | $80,096 |
| OzempicSemaglutide | 58 | $77,563 |
| LinzessLinaclotide | 40 | $40,392 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $37,888 |
| EliquisApixaban | 20 | $25,348 |
| VascepaIcosapent Ethyl | 29 | $24,309 |
| TrulicityDulaglutide | 18 | $20,205 |
| TradjentaLinagliptin | 15 | $18,054 |
| JanuviaSitagliptin Phosphate | 16 | $11,691 |
| MounjaroTirzepatide | 13 | $10,807 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $6,625 |
| Rosuvastatin Calcium | 251 | $5,387 |
| Omeprazole | 162 | $3,297 |
| Atorvastatin Calcium | 265 | $2,540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,182 | $124,609128 claims |
| Boehringer IngelheimJardiance, Tradjenta | $712 | $106,215106 claims |
| Novo NordiskOzempic | $1,060 | $77,56358 claims |
| AbbVieLinzess | $854 | $40,39240 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $531 | $31,01231 claims |
| PfizerEliquis | $293 | $25,34820 claims |
| MerckJanuvia | $59 | $11,69116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 748 medical providers in Arizona.
Other medical in Glendale
- Kaitlyn HasanGlendale$16K
- Molly MoloznikGlendale$9K
- Robert CasquejoScottsdale$474K
- Andrew HicksPeoria$460K
- Darren WestScottsdale$206K
- Linda MoorsTucson$122K
- Jamie WystrachScottsdale$79K
- Scott YoungPhoenix$69K
- Scott LightfootPhoenix$61K
- Jennifer KiserPhoenix$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.